Lee Se Na, Sohn Ji Yeon, Kong Jung Hee, Eom Hyeon Seok, Lee Hyewon, Kong Sun Young
Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center, Goyang, Korea.
Center for Hematologic Malignancy, National Cancer Center, Goyang, Korea.
Ann Lab Med. 2017 Jul;37(4):327-330. doi: 10.3343/alm.2017.37.4.327.
Peripheral blood stem cell (PBSC) transplantation following myeloablative therapy is a mainstay of treatment for various types of malignancies. This study aimed to evaluate the differences between the Optia MNC and COBE Spectra MNC systems (Terumo BCT, Japan) according to apheresis procedures and the parameters of apheresis, products, and collection. The clinical data of 74 patients who underwent autologous PBSC collection from July 2012 to July 2015 were reviewed retrospectively. The patients comprised 48 (65%) men and 26 (35%) women with a median age of 56 yr (range, 23-66 yr). Of 216 procedures, 111 (51%) and 105 (49%) were processed by using COBE and Optia MNC, respectively. PBSC collection rates, throughput, numbers of stem cells retrieved, collection efficacy, and platelet loss were compared. There were no significant differences in the median CD34+ cell counts of collected products (0.61×10⁸ vs 0.94×10⁸), CD34 collection efficiency (43.5% vs 42.1%), and loss of platelets (40.1% vs 44.7%). The Spectra Optia MNC apheresis system was comparable to the COBE Spectra system in collecting autologous CD34+ hematopoietic stem cells and retention of platelets.
清髓性治疗后进行外周血干细胞（PBSC）移植是各类恶性肿瘤治疗的主要手段。本研究旨在根据单采程序以及单采、产品和采集的参数，评估Optia多能细胞（MNC）和COBE Spectra MNC系统（日本泰尔茂血液治疗株式会社）之间的差异。回顾性分析了2012年7月至2015年7月期间接受自体PBSC采集的74例患者的临床资料。患者包括48例（65%）男性和26例（35%）女性，中位年龄为56岁（范围23 - 66岁）。在216次程序中，分别使用COBE和Optia MNC处理了111次（51%）和105次（49%）。比较了PBSC采集率、通量、回收的干细胞数量、采集效率和血小板损失。采集产品的中位CD34⁺细胞计数（0.61×10⁸对0.94×10⁸）、CD34采集效率（43.5%对42.1%）和血小板损失（40.1%对44.7%）无显著差异。Spectra Optia MNC单采系统在采集自体CD34⁺造血干细胞和保留血小板方面与COBE Spectra系统相当。
